AbbVie, Inc.  Securities Fraud Class Action

AbbVie, Inc. Securities Fraud Class Action

CompanyAbbVie, Inc.
CourtUnited States District Court for the Northern District of Illinois
Case Number22-cv-01773
JudgeHonorable Harry D. Leinenweber
Class PeriodApril 30, 2021 through August 31, 2021
Security TypeSecurities

Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired AbbVie, Inc. (“AbbVie”) (NYSE: ABBV) securities between April 30, 2021 and August 31, 2021, inclusive (the “Class Period”).

The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, about the company’s business and operations.  Specifically, Defendants misrepresented and/or failed to disclose that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) therefore, Defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis at all relevant times.

Current Status of Case:
On February 16, 2023, Plaintiff filed a Notice of Voluntary Dismissal, and the Court dismissed the case on January 30, 2024. This action has concluded.

If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at [email protected]. If you would like additional information about the suit, please click on the link “Submit Your Information” above and fill out the form as promptly as possible.

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent. 

Complete this form with your transactions in AbbVie, Inc. between April 30, 2021 through August 31, 2021.

    Submit Your Information
    SUBMIT YOUR INFORMATION
    * Denotes required field
    Phone Country code
    Purchase Information
    Sales Information
    Did you purchase shares of AbbVie, Inc. prior to the Class Period?
    Are you a current or former employee of AbbVie, Inc.?
    The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kessler Topaz or you to file a lead plaintiff motion in this matter. READ MORE
    I agree to the KTMC disclaimer
    I would like to receive new case alerts by email
    Scroll to Top